La chemioterapia con cisplatino e paclitaxel nel carcinoma della cervice localmente avanzato: Ha ancora un ruolo questo regime nella terapia neoadiuvante?

Translated title of the contribution: Chemotherapy with cisplatin and paclitaxel in locally advanced cervical cancer: Has this regimen still a role as neoadjuvant setting?

M. Moioli, A. Papadia, S. Mammoliti, E. Pacella, S. Menoni, M. V. Menada, N. Ragni

Research output: Contribution to journalArticlepeer-review

Abstract

Aim. Neoadjuvant chemotherapy represents a promising alternative to concomitant chemoradiation therapy in locally advanced cervical cancer patients. The aim of this study was the evaluation of pathologic response rates, toxicity and predictors of response in locally advanced cervical cancer patients treated with neoadjuvant cisplatin and paclitaxel followed by radical surgery. Methods. Fourteen patients with stage IB2 to HB cervical cancer received three cycles of cisplatin 75 mg/m 2 and paclitaxel 175 mg/m 2 intravenously every three weeks followed by radical hysterectomy and bilateral pelvic lymphadenectomy. Toxicity, pathologic response and predictors of response were evaluated. Results. Chemotherapy related toxicities were as follows: alopecia 100%, asthenia 35.7%; nausea and vomiting 14.3%; paclitaxel hypersensitivity 7.1%, neutropenia 7.1%. Optimal, partial and no pathologic response was achieved in 21.4%, 64.3% and 14.2% of the patients, respectively. Based on lack of pathologic risk factors, 43% of the patients did not receive any adjuvant radiotherapy. Better response rates were obtained in patients with stage IIB, tumor diameter 12 g/dL and SCC antigen

Translated title of the contributionChemotherapy with cisplatin and paclitaxel in locally advanced cervical cancer: Has this regimen still a role as neoadjuvant setting?
Original languageItalian
Pages (from-to)95-107
Number of pages13
JournalMinerva Ginecologica
Volume64
Issue number2
Publication statusPublished - Apr 2012

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Fingerprint Dive into the research topics of 'Chemotherapy with cisplatin and paclitaxel in locally advanced cervical cancer: Has this regimen still a role as neoadjuvant setting?'. Together they form a unique fingerprint.

Cite this